CancerIQ
Hackensack Meridien Health Launches Cancer Risk, Early Detection Program; Eyes Multi-Cancer Testing
Premium
Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.
CancerIQ Closes $14M Series B Funding Round
The cancer precision medicine technology firm will look to expand development of its bioinformatics platform, add staff, and grow its partnerships and customer base.
CancerIQ Lands $4.8M to Expand Genetic Risk Management Platform, Integrate With EMRs
The Chicago-based precision medicine software startup raised the funds through a Series A round led by digital health-focused venture capital firm HealthX Ventures.
The health system said that the program is encouraging patient compliance and increasing revenues and savings.